Beyond monoamines: II. Novel applications for PET imaging in psychiatric disorders.

Autor: Royse SK; Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Lopresti BJ; Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Mathis CA; Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Tollefson S; Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA., Narendran R; Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.; Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Jazyk: angličtina
Zdroj: Journal of neurochemistry [J Neurochem] 2023 Feb; Vol. 164 (3), pp. 401-443. Date of Electronic Publication: 2022 Jul 29.
DOI: 10.1111/jnc.15657
Abstrakt: Early applications of positron emission tomography (PET) in psychiatry sought to identify derangements of cerebral blood flow and metabolism. The need for more specific neurochemical imaging probes was soon evident, and these probes initially targeted the sites of action of neuroleptic (dopamine D 2 receptors) and psychoactive (serotonin receptors) drugs. For nearly 30 years, the centrality of monoamine dysfunction in psychiatric disorders drove the development of an armamentarium of monoaminergic PET radiopharmaceuticals and imaging methodologies. However, continued investments in monoamine-enhancing drug development realized only modest gains in efficacy and tolerability. As patent protection for many widely prescribed and profitable psychiatric drugs lapsed, drug development pipelines shifted away from monoamines in search of novel targets with the promises of improved efficacy, or abandoned altogether. Over this period, PET radiopharmaceutical development activities closely parallelled drug development priorities, resulting in the development of new PET imaging agents for non-monoamine targets. In part two of this review, we survey clinical research studies using the novel targets and radiotracers described in part one across major psychiatric application areas such as substance use disorders, anxiety disorders, eating disorders, personality disorders, mood disorders, and schizophrenia. Important limitations of the studies described are discussed, as well as key methodologic issues, challenges to the field, and the status of clinical trials seeking to exploit these targets for novel therapeutics.
(© 2022 International Society for Neurochemistry.)
Databáze: MEDLINE
Externí odkaz: